Perkenalan
Halaman ini memberikan analisis komprehensif tentang riwayat insider trading yang diketahui di Noubar Afeyan. Insider adalah pejabat, direktur, atau investor penting dalam suatu perusahaan. Adalah ilegal bagi insider untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik dan non-publik. Hal ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan ke SEC melalui Formulir 4. Meskipun ada pembatasan ini, penelitian akademis menunjukkan bahwa insider – secara umum – cenderung mengungguli pasar di perusahaan mereka sendiri.
Profitabilitas Perdagangan Rata-rata
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari seluruh pembelian pasar terbuka yang dilakukan oleh insider dalam 3 tahun terakhir. Untuk menghitungnya, kami memeriksa setiap pembelian pasar terbuka dan tidak terencana yang dilakukan oleh insider, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata perdagangan tersebut selama 3, 6, dan 12 bulan, merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami menghitung rata-rata semua metrik kinerja untuk menghitung metrik kinerja bagi insider. Daftar ini hanya mencakup insider yang telah melakukan setidaknya tiga perdagangan dalam 2 tahun terakhir.
Jika profitabilitas perdagangan insider ini adalah "T/A", maka insider tersebut belum melakukan pembelian di pasar terbuka dalam 3 tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang dapat diandalkan.
Frekuensi Pembaruan: Harian
Perusahaan dengan Posisi Insider yang Dilaporkan
Pengajuan SEC menunjukkan Noubar Afeyan telah melaporkan kepemilikan atau perdagangan di perusahaan berikut:
Bagaimana Menafsirkan Grafik
Bagan berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka dan tidak terencana yang dilakukan oleh Noubar Afeyan. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham dipetakan sebagai persentase perubahan kumulatif harga saham. Misalnya, jika perdagangan insider dilakukan pada tanggal 1 Januari 2019, grafik akan menunjukkan persentase perubahan harian sekuritas hingga hari ini. Jika harga saham naik dari $10 menjadi $15 selama waktu ini, persentase perubahan harga saham kumulatif akan menjadi 50%. Perubahan harga dari $10 menjadi $20 adalah 100%, dan perubahan harga dari $10 menjadi $5 adalah -50%.
Pada akhirnya, kami mencoba untuk menentukan seberapa dekat korelasi perdagangan insider dengan keuntungan berlebih (positif atau negatif) pada harga saham untuk melihat apakah insider mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi insider. Pertimbangkan situasi di mana insider melakukan hal ini. Dalam situasi ini, kita mengharapkan (a) keuntungan positif setelah pembelian, atau (b) keuntungan negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, yang menunjukkan keuntungan positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, yang menunjukkan keuntungan negatif setelah setiap transaksi penjualan.
Namun, hal ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam kenaikan non-siklus selama bertahun-tahun, maka kita perkirakan semua lahan pasca pembelian akan miring ke atas. Demikian pula, penurunan non-siklus selama bertahun-tahun akan mengakibatkan penurunan pasca-perdagangan. Tak satu pun dari grafik ini menunjukkan aktivitas insider trading.
Indikator terkuat adalah situasi di mana harga saham sangat bersiklus, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat memberi isyarat kepada insider yang mengatur waktu perdagangan demi keuntungan finansial mereka.
Pembelian Insider AGIO / Agios Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider AGIO / Agios Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider BGMD / BG Medicine, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider BGMD / BG Medicine, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider CARM / Carisma Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider CARM / Carisma Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider EDIT / Editas Medicine, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider EDIT / Editas Medicine, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider EVLO / Evelo Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider EVLO / Evelo Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider FHTX / Foghorn Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider FHTX / Foghorn Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider KLDO / Kaleido Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider KLDO / Kaleido Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider MCRB / Seres Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider MCRB / Seres Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider QTRX / Quanterix Corporation - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider QTRX / Quanterix Corporation - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider RNAC / Cartesian Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider RNAC / Cartesian Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider SANA / Sana Biotechnology, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider SANA / Sana Biotechnology, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider SYRS / Syros Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider SYRS / Syros Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider TMDX / TransMedics Group, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider TMDX / TransMedics Group, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Riwayat Insider Trading
Tabel ini menunjukkan daftar lengkap perdagangan insider yang dilakukan oleh Noubar Afeyan sebagaimana diungkapkan kepada Securities Exchange Commission (SEC).
| Tanggal Berkas | Tanggal Trans | Formulir | Kode | Keamanan | Kode | Saham | Sisa Saham | Persen Mengubah |
Saham Harga |
Trans Nilai |
Tersisa Nilai |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -9.263 | 3.924 | -70,24 | 46,84 | -433.879 | 183.800 | |
| 2026-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 9.263 | 13.187 | 236,06 | 19,15 | 177.386 | 252.531 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 1.562.500 | 16,00 | 25.000.000 | 25.000.000 | ||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 4.340.252 | 56,25 | 16,00 | 25.000.000 | 69.444.032 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 15.264.724 | 11,40 | 16,00 | 25.000.000 | 244.235.584 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2.777.752 | 2.777.752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2.777.752 | 2.777.752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 987.491 | 987.491 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 13.702.224 | 13.702.224 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 12.723.940 | 12.723.940 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 1.562.500 | 16,00 | 25.000.000 | 25.000.000 | ||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 4.340.252 | 56,25 | 16,00 | 25.000.000 | 69.444.032 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1.562.500 | 15.264.724 | 11,40 | 16,00 | 25.000.000 | 244.235.584 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2.777.752 | 2.777.752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2.777.752 | 2.777.752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 987.491 | 987.491 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 13.702.224 | 13.702.224 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 12.723.940 | 12.723.940 | |||||
| 2026-02-26 | 3 | GENB |
Generate Biomedicines, Inc.
Common Stock |
25.016.458 | ||||||||
| 2026-02-26 | 3 | GENB |
Generate Biomedicines, Inc.
Common Stock |
25.016.458 | ||||||||
| 2025-12-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23.853 | 3.924 | -85,87 | 29,48 | -703.306 | 115.699 | |
| 2025-12-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 23.853 | 27.777 | 607,87 | 10,90 | 259.998 | 302.769 | |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.309 | 2.224.015 | -0,06 | 121,62 | -159.204 | 270.491.154 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.428 | 2.225.324 | -0,15 | 120,88 | -414.377 | 268.997.610 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.664 | 2.228.752 | -0,25 | 119,84 | -678.754 | 267.085.839 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.599 | 2.234.416 | -0,21 | 118,96 | -547.107 | 265.811.043 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.000 | 2.239.015 | -0,09 | 119,01 | -238.026 | 266.471.892 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.832 | 2.241.015 | -0,30 | 118,30 | -808.208 | 265.106.248 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.500 | 2.247.847 | -0,16 | 117,25 | -410.376 | 263.560.960 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.668 | 2.251.347 | -0,12 | 116,33 | -310.362 | 261.893.568 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2.254.015 | -0,03 | 124,61 | -87.230 | 280.882.501 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.699 | 2.254.715 | -0,30 | 123,82 | -829.478 | 279.181.517 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.900 | 2.261.414 | -0,13 | 122,86 | -356.298 | 277.840.490 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.100 | 2.264.314 | -0,09 | 121,57 | -255.297 | 275.272.427 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.601 | 2.266.414 | -0,11 | 120,86 | -314.347 | 273.910.637 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2.269.015 | -0,02 | 119,95 | -59.976 | 272.172.887 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 2.269.515 | -0,05 | 119,28 | -131.211 | 270.714.331 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.000 | 2.270.615 | -0,13 | 117,83 | -353.483 | 267.541.116 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.279 | 2.273.615 | -0,19 | 117,18 | -501.418 | 266.424.934 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.121 | 2.277.894 | -0,27 | 116,01 | -710.089 | 264.255.294 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2.284.015 | 0,00 | 134,05 | -13.405 | 306.172.211 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2.284.115 | -0,03 | 131,56 | -92.089 | 300.488.348 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.705 | 2.284.815 | -0,12 | 130,76 | -353.695 | 298.753.270 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.300 | 2.287.520 | -0,10 | 129,84 | -298.631 | 297.010.911 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.435 | 2.289.820 | -0,06 | 128,78 | -184.798 | 294.880.501 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 2.291.255 | -0,05 | 127,50 | -140.254 | 292.143.032 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 2.292.355 | -0,05 | 125,71 | -138.277 | 288.163.695 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.500 | 2.293.455 | -0,07 | 124,90 | -187.352 | 286.455.970 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.600 | 2.294.955 | -0,07 | 123,74 | -197.978 | 283.969.240 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.460 | 2.296.555 | -0,11 | 122,69 | -301.814 | 281.761.347 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2.299.015 | 0,00 | 136,92 | -13.692 | 314.781.134 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.299.115 | -0,01 | 135,02 | -27.003 | 310.415.012 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.840 | 2.299.315 | -0,30 | 134,09 | -917.197 | 308.322.506 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.160 | 2.306.155 | -0,27 | 133,26 | -820.887 | 307.320.291 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.700 | 2.312.315 | -0,07 | 132,22 | -224.782 | 305.744.695 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.314.015 | -0,01 | 150,24 | -30.048 | 347.657.614 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.400 | 2.314.215 | -0,06 | 149,39 | -209.150 | 345.726.827 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.601 | 2.315.615 | -0,07 | 148,61 | -237.929 | 344.130.492 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.397 | 2.317.216 | -0,28 | 147,55 | -943.876 | 341.904.757 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.031 | 2.323.613 | -0,13 | 146,55 | -444.188 | 340.521.535 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.263 | 2.326.644 | -0,05 | 145,57 | -183.861 | 338.700.735 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -408 | 2.327.907 | -0,02 | 144,46 | -58.940 | 336.293.868 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2.328.315 | -0,03 | 142,97 | -100.079 | 332.878.264 |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1.232 | 1.528.557 | -0,08 | 149,40 | -184.065 | 228.372.224 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -6.420 | 7.930.725 | -0,08 | 149,40 | -959.172 | 1.184.880.452 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31.531 | 1.529.789 | -2,02 | 148,29 | -4.675.871 | 226.859.142 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -163.649 | 7.937.145 | -2,02 | 148,29 | -24.268.230 | 1.177.034.155 | |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.721 | 1.946.931 | -0,09 | 154,86 | -266.510 | 301.497.257 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1.948.652 | -0,02 | 153,71 | -61.484 | 299.527.299 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.437 | 1.949.052 | -0,12 | 152,90 | -372.606 | 298.001.085 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.902 | 1.951.489 | -0,20 | 151,76 | -592.172 | 296.160.312 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.840 | 1.955.391 | -0,15 | 151,07 | -429.033 | 295.396.812 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1.958.231 | -0,02 | 149,35 | -44.805 | 292.461.800 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.800 | 1.958.531 | -0,09 | 148,57 | -267.428 | 290.980.909 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1.960.331 | -0,04 | 147,78 | -103.443 | 289.688.698 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 1.961.031 | -0,05 | 145,91 | -131.323 | 286.142.662 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.177 | 1.961.931 | -0,16 | 148,06 | -470.379 | 290.478.599 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.229 | 1.965.108 | -0,11 | 146,82 | -327.261 | 288.516.567 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.581 | 1.967.337 | -0,28 | 146,02 | -814.937 | 287.270.155 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.400 | 1.972.918 | -0,12 | 144,99 | -347.966 | 286.045.095 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.500 | 1.975.318 | -0,08 | 143,94 | -215.913 | 284.331.224 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 1.976.818 | -0,06 | 142,82 | -157.102 | 282.329.147 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.013 | 1.977.918 | -0,15 | 141,72 | -427.017 | 280.320.429 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.000 | 1.980.931 | -0,05 | 141,01 | -141.010 | 279.331.080 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -97 | 1.981.931 | 0,00 | 164,67 | -15.973 | 326.364.578 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -625 | 1.982.028 | -0,03 | 163,92 | -102.451 | 324.896.408 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.223 | 1.982.653 | -0,11 | 163,02 | -362.401 | 323.219.230 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.005 | 1.984.876 | -0,05 | 162,19 | -163.003 | 321.930.611 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -825 | 1.985.881 | -0,04 | 160,24 | -132.194 | 318.208.635 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.200 | 1.986.706 | -0,11 | 159,57 | -351.050 | 317.015.299 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.923 | 1.988.906 | -0,10 | 158,25 | -304.320 | 314.750.142 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.802 | 1.990.829 | -0,09 | 157,41 | -283.656 | 313.379.777 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1.992.631 | -0,03 | 155,66 | -93.396 | 310.172.941 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1.993.231 | -0,01 | 153,84 | -30.768 | 306.638.657 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -800 | 1.993.431 | -0,04 | 152,92 | -122.336 | 304.835.469 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1.994.231 | -0,04 | 151,73 | -106.213 | 302.590.453 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1.994.931 | -0,02 | 150,60 | -60.238 | 300.426.634 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1.995.331 | -0,02 | 149,45 | -44.836 | 298.208.803 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1.995.631 | -0,03 | 148,21 | -88.924 | 295.765.885 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1.996.231 | -0,02 | 147,06 | -44.119 | 293.572.318 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1.996.531 | -0,01 | 145,03 | -14.503 | 289.556.891 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1.996.631 | -0,01 | 144,40 | -28.879 | 288.303.533 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1.996.831 | -0,01 | 142,95 | -14.295 | 285.446.991 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1.996.931 | -0,01 | 129,15 | -25.830 | 257.903.639 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.711 | 1.997.131 | -0,29 | 128,75 | -735.272 | 257.123.826 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.600 | 2.002.842 | -0,13 | 127,71 | -332.036 | 255.775.541 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.001 | 2.005.442 | -0,10 | 126,62 | -253.368 | 253.930.670 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.488 | 2.007.443 | -0,22 | 125,53 | -563.357 | 251.984.483 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7.996 | 2.011.931 | -0,40 | 122,07 | -976.063 | 245.594.204 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.004 | 2.019.927 | -0,25 | 121,59 | -608.416 | 245.594.844 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.000 | 2.024.931 | -0,10 | 120,37 | -240.741 | 243.741.957 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2.026.931 | -0,03 | 113,40 | -79.379 | 229.851.138 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.500 | 2.027.631 | -0,07 | 112,77 | -169.151 | 228.650.473 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.246 | 2.029.131 | -0,21 | 111,55 | -473.650 | 226.353.621 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.572 | 2.033.377 | -0,22 | 110,42 | -504.860 | 224.534.232 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.982 | 2.037.949 | -0,20 | 109,70 | -436.815 | 223.557.707 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 2.041.931 | -0,05 | 109,91 | -120.901 | 224.428.636 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.153 | 2.043.031 | -0,20 | 109,04 | -452.847 | 222.774.143 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.821 | 2.047.184 | -0,28 | 108,30 | -630.388 | 221.700.815 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.926 | 2.053.005 | -0,19 | 107,16 | -420.700 | 219.994.473 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -282 | 2.056.931 | -0,01 | 104,49 | -29.466 | 214.927.897 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.475 | 2.057.213 | -0,31 | 103,69 | -671.398 | 213.314.062 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8.243 | 2.063.688 | -0,40 | 103,10 | -849.839 | 212.762.725 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -389 | 2.071.931 | -0,02 | 109,36 | -42.542 | 226.592.176 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -748 | 2.072.320 | -0,04 | 108,56 | -81.205 | 224.977.483 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7.512 | 2.073.068 | -0,36 | 107,31 | -806.136 | 222.467.354 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.351 | 2.080.580 | -0,30 | 106,59 | -676.982 | 221.778.385 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2.086.931 | 0,00 | 104,15 | -10.415 | 217.353.864 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.702 | 2.087.031 | -0,13 | 103,64 | -280.044 | 216.306.363 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.500 | 2.089.733 | -0,17 | 102,64 | -359.252 | 214.497.091 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.832 | 2.093.233 | -0,18 | 101,33 | -388.289 | 212.103.113 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.167 | 2.097.065 | -0,15 | 100,66 | -318.775 | 211.080.497 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.499 | 2.100.232 | -0,07 | 99,40 | -149.000 | 208.762.221 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.101.731 | -0,01 | 97,47 | -19.494 | 204.855.721 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.973 | 2.101.931 | -0,14 | 110,75 | -329.256 | 232.785.916 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.544 | 2.104.904 | -0,22 | 110,24 | -500.931 | 232.044.827 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.100 | 2.109.448 | -0,15 | 109,09 | -338.176 | 230.117.362 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.466 | 2.112.548 | -0,07 | 107,79 | -158.020 | 227.711.126 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.100 | 2.114.014 | -0,05 | 106,71 | -117.376 | 225.577.344 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.817 | 2.115.114 | -0,09 | 105,73 | -192.106 | 223.624.446 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.778 | 2.116.931 | -0,27 | 103,18 | -596.147 | 218.414.991 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7.109 | 2.122.709 | -0,33 | 102,15 | -726.159 | 216.827.083 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.113 | 2.129.818 | -0,10 | 101,05 | -213.514 | 215.213.849 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.131.931 | -0,01 | 112,44 | -22.487 | 239.703.662 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.404 | 2.132.131 | -0,07 | 111,69 | -156.806 | 238.127.264 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.803 | 2.133.535 | -0,18 | 110,80 | -421.373 | 236.395.891 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -412 | 2.137.338 | -0,02 | 109,50 | -45.113 | 234.033.381 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2.137.750 | -0,03 | 108,52 | -65.109 | 231.977.941 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.300 | 2.138.350 | -0,11 | 107,66 | -247.617 | 230.213.692 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.281 | 2.140.650 | -0,29 | 106,60 | -669.527 | 228.183.871 |
| 2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8.100 | 2.146.931 | -0,38 | 76,17 | -616.966 | 163.528.729 |
| 2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.900 | 2.155.031 | -0,09 | 75,30 | -143.066 | 162.269.309 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2.156.931 | -0,02 | 78,42 | -31.366 | 169.135.744 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.100 | 2.157.331 | -0,14 | 77,34 | -239.754 | 166.847.764 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.500 | 2.160.431 | -0,30 | 76,73 | -498.734 | 165.766.198 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2.166.931 | 0,00 | 105,58 | -10.558 | 228.784.575 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2.167.031 | -0,02 | 104,82 | -52.408 | 227.139.521 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.700 | 2.167.531 | -0,26 | 103,76 | -591.421 | 224.898.681 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8.700 | 2.173.231 | -0,40 | 102,88 | -895.054 | 223.581.571 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.866 | 2.181.931 | -0,18 | 104,04 | -402.206 | 227.001.119 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.604 | 2.185.797 | -0,26 | 103,22 | -578.445 | 225.618.185 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.700 | 2.191.401 | -0,12 | 102,03 | -275.486 | 223.592.369 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.800 | 2.194.101 | -0,08 | 100,94 | -181.690 | 221.470.141 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.030 | 2.195.901 | -0,05 | 100,02 | -103.018 | 219.628.748 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.196.931 | -0,01 | 100,16 | -20.033 | 220.055.594 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.596 | 2.197.131 | -0,21 | 99,49 | -457.245 | 218.587.510 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.204 | 2.201.727 | -0,24 | 98,46 | -512.367 | 216.774.114 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.006 | 2.206.931 | -0,05 | 105,77 | -106.404 | 233.424.885 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.380 | 2.207.937 | -0,42 | 105,06 | -985.422 | 231.956.146 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.614 | 2.217.317 | -0,21 | 103,87 | -479.265 | 230.316.930 |
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -70.813 | 0 | -100,00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2.431.281 | 7.293.841 | -25,00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -1.181.745 | 0 | -100,00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -345.069 | 1.035.208 | -25,00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -4.926.378 | 8.057.470 | -37,94 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2.825.989 | 8.615.337 | -24,70 | ||||
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2.221.931 | 0,00 | 114,32 | -11.432 | 254.011.152 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250 | 2.222.031 | -0,01 | 113,22 | -28.305 | 251.578.350 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2.222.281 | -0,04 | 112,17 | -100.957 | 249.283.038 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.895 | 2.223.181 | -0,17 | 111,23 | -433.243 | 247.285.757 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.400 | 2.227.076 | -0,06 | 110,26 | -154.363 | 245.555.841 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.174 | 2.228.476 | -0,19 | 108,77 | -453.992 | 242.383.981 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.281 | 2.232.650 | -0,19 | 108,21 | -463.229 | 241.585.903 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1.982.209 | -0,02 | 108,91 | -32.674 | 215.888.923 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.689 | 1.982.509 | -0,29 | 108,07 | -614.811 | 214.250.144 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.011 | 1.988.198 | -0,45 | 107,27 | -966.608 | 213.273.602 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1.997.209 | -0,01 | 117,21 | -11.721 | 234.092.867 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.336 | 1.997.309 | -0,22 | 116,57 | -505.463 | 232.833.500 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.717 | 2.001.645 | -0,24 | 115,43 | -544.460 | 231.040.074 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.847 | 2.006.362 | -0,29 | 114,64 | -670.307 | 230.011.547 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2.012.209 | -0,01 | 116,46 | -34.938 | 234.341.860 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.878 | 2.012.509 | -0,49 | 115,84 | -1.144.313 | 233.138.300 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.657 | 2.022.387 | -0,18 | 115,16 | -421.125 | 232.889.593 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -854 | 2.026.044 | -0,04 | 113,83 | -97.215 | 230.633.503 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -311 | 2.026.898 | -0,02 | 112,61 | -35.022 | 228.252.227 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2.027.209 | -0,01 | 99,50 | -29.850 | 201.707.296 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.000 | 2.027.509 | -0,20 | 98,82 | -395.289 | 200.362.900 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.200 | 2.031.509 | -0,06 | 98,07 | -117.679 | 199.221.555 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.900 | 2.032.709 | -0,14 | 96,44 | -279.672 | 196.031.813 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.600 | 2.035.609 | -0,08 | 95,70 | -153.124 | 194.812.870 |
| 2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -113.960 | 0 | -100,00 | 14,92 | -1.700.283 | ||
| 2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -683.760 | 0 | -100,00 | 14,92 | -10.201.699 | ||
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2.037.209 | -0,01 | 113,68 | -22.735 | 231.579.733 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2.037.409 | -0,04 | 112,59 | -101.328 | 229.385.156 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.175 | 2.038.309 | -0,20 | 111,46 | -465.349 | 227.191.552 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.725 | 2.042.484 | -0,47 | 110,59 | -1.075.464 | 225.873.404 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.101 | 2.052.209 | -0,05 | 121,29 | -133.544 | 248.920.023 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11.499 | 2.053.310 | -0,56 | 120,50 | -1.385.632 | 247.424.266 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.400 | 2.064.809 | -0,12 | 119,61 | -287.053 | 246.962.306 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.149 | 2.067.209 | -0,25 | 126,08 | -649.185 | 260.633.504 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.004 | 2.072.358 | -0,43 | 125,26 | -1.127.819 | 259.578.589 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -847 | 2.081.362 | -0,04 | 124,14 | -105.147 | 258.382.152 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2.082.209 | -0,01 | 127,15 | -38.145 | 264.752.874 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.845 | 2.082.509 | -0,33 | 126,27 | -864.316 | 262.957.787 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.865 | 2.089.354 | -0,28 | 125,61 | -736.678 | 262.434.981 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.990 | 2.095.219 | -0,09 | 124,59 | -247.942 | 261.051.926 |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 3.246.753 | 3.931.685 | 474,03 | 2,31 | 7.499.999 | 9.082.192 | |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.082.251 | 1.493.241 | 263,33 | 2,31 | 2.500.000 | 3.449.387 | |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.082.251 | 1.493.241 | 263,33 | 2,31 | 2.500.000 | 3.449.387 | |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -170 | 2.097.209 | -0,01 | 128,17 | -21.789 | 268.801.794 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.549 | 2.097.379 | -0,07 | 127,55 | -197.577 | 267.523.628 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.012 | 2.098.928 | -0,05 | 126,54 | -128.055 | 265.590.793 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.639 | 2.099.940 | -0,13 | 125,14 | -330.258 | 262.796.991 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.097 | 2.102.579 | -0,29 | 124,17 | -757.086 | 261.084.593 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.533 | 2.108.676 | -0,17 | 123,46 | -436.169 | 260.327.861 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.096 | 2.112.209 | -0,10 | 122,82 | -257.441 | 259.432.070 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8.073 | 2.114.305 | -0,38 | 121,87 | -983.873 | 257.674.790 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.131 | 2.122.378 | -0,15 | 120,77 | -378.123 | 256.314.073 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.700 | 2.125.509 | -0,08 | 119,84 | -203.723 | 254.714.835 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2.127.209 | -0,02 | 123,48 | -49.390 | 262.657.131 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.790 | 2.127.609 | -0,32 | 122,26 | -830.175 | 260.130.838 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7.810 | 2.134.399 | -0,36 | 121,60 | -949.662 | 259.533.527 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -530 | 2.142.209 | -0,02 | 128,15 | -67.918 | 274.516.371 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.002 | 2.142.739 | -0,14 | 127,19 | -381.823 | 272.533.902 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.997 | 2.145.741 | -0,28 | 126,17 | -756.658 | 270.734.150 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.471 | 2.151.738 | -0,25 | 125,43 | -686.229 | 269.892.928 |
| 2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.702 | 2.157.209 | -0,13 | 126,59 | -342.054 | 273.087.343 |
| 2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -12.298 | 2.159.911 | -0,57 | 125,76 | -1.546.547 | 271.621.768 |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22.760 | 1.380.277 | -1,62 | 6,24 | -142.016 | 8.612.514 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -177.240 | 10.743.293 | -1,62 | 6,24 | -1.105.924 | 67.034.925 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22.297 | 1.403.037 | -1,56 | 6,31 | -140.607 | 8.847.692 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -181.461 | 10.920.533 | -1,63 | 6,31 | -1.144.311 | 68.865.973 | |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2.172.209 | -0,03 | 129,68 | -77.807 | 281.688.370 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.441 | 2.172.809 | -0,11 | 128,55 | -313.780 | 279.305.037 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5.637 | 2.175.250 | -0,26 | 127,84 | -720.629 | 278.082.002 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.373 | 2.180.887 | -0,15 | 126,72 | -427.440 | 276.370.942 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.949 | 2.184.260 | -0,13 | 125,69 | -370.666 | 274.544.226 |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -9.330 | 1.425.334 | -0,65 | 6,23 | -58.093 | 8.874.842 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -72.670 | 11.101.994 | -0,65 | 6,23 | -452.480 | 69.126.566 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -13.127 | 1.434.664 | -0,91 | 6,35 | -83.385 | 9.113.273 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -102.245 | 11.174.664 | -0,91 | 6,35 | -649.481 | 70.983.701 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -39.580 | 1.447.791 | -2,66 | 6,57 | -259.851 | 9.505.037 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -308.290 | 11.276.909 | -2,66 | 6,57 | -2.023.986 | 74.035.163 | |
| 2023-03-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.187.209 | -0,46 | 139,00 | -1.390.000 | 304.022.051 |
| 2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1.329.324 | 1.329.324 | 5,78 | 7.683.493 | 7.683.493 | ||
| 2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1.993.986 | 7.508.693 | 36,16 | 5,78 | 11.525.239 | 43.400.246 | |
| 2023-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.197.209 | -0,45 | 160,35 | -1.603.500 | 352.322.463 |
| 2023-02-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.207.209 | -0,45 | 173,17 | -1.731.700 | 382.222.383 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11.000 | 2.217.209 | -0,49 | 169,32 | -1.862.516 | 375.416.941 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.100 | 2.228.209 | -0,09 | 168,27 | -353.364 | 374.937.609 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2.230.309 | -0,01 | 166,59 | -49.977 | 371.547.176 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3.700 | 2.230.609 | -0,17 | 165,83 | -613.577 | 369.905.459 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2.900 | 2.234.309 | -0,13 | 164,60 | -477.327 | 367.757.430 |
| 2023-01-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.237.209 | -0,44 | 194,33 | -1.943.300 | 434.756.825 |
| 2023-01-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.247.209 | -0,44 | 200,20 | -2.002.000 | 449.891.242 |
| 2023-01-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.257.209 | -0,44 | 188,57 | -1.885.700 | 425.641.901 |
| 2023-01-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.267.209 | -0,44 | 182,15 | -1.821.500 | 412.972.119 |
| 2022-12-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.277.209 | -0,44 | 201,70 | -2.017.000 | 459.313.055 |
| 2022-12-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.287.209 | -0,44 | 195,00 | -1.950.000 | 446.005.755 |
| 2022-12-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.297.209 | -0,43 | 172,16 | -1.721.600 | 395.487.501 |
| 2022-12-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.307.209 | -0,43 | 173,52 | -1.735.200 | 400.346.906 |
| 2022-11-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.317.209 | -0,43 | 178,01 | -1.780.100 | 412.486.374 |
| 2022-11-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.327.209 | -0,43 | 184,25 | -1.842.500 | 428.788.258 |
| 2022-11-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.337.209 | -0,43 | 162,50 | -1.625.000 | 379.796.462 |
| 2022-11-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.347.209 | -0,42 | 154,20 | -1.542.000 | 361.939.628 |
| 2022-10-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.357.209 | -0,42 | 137,25 | -1.372.500 | 323.526.935 |
| 2022-10-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.367.209 | -0,42 | 132,50 | -1.325.000 | 313.655.192 |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3.048.780 | 3.048.780 | 1,64 | 4.999.999 | 4.999.999 | ||
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 919.111 | 6.299.611 | 17,08 | 1,64 | 1.507.342 | 10.331.362 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 914.634 | 5.380.500 | 20,48 | 1,64 | 1.500.000 | 8.824.020 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.757.333 | 14.101.638 | 24,31 | 1,64 | 4.522.026 | 23.126.686 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.743.902 | 11.344.305 | 31,90 | 1,64 | 4.499.999 | 18.604.660 | |
| 2022-10-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.377.209 | -0,42 | 135,36 | -1.353.600 | 321.779.010 |
| 2022-10-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.387.209 | -0,42 | 122,40 | -1.224.000 | 292.194.382 |
| 2022-09-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.397.209 | -0,42 | 123,58 | -1.235.800 | 296.247.088 |
| 2022-09-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.407.209 | -0,41 | 130,37 | -1.303.700 | 313.827.837 |
| 2022-09-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.417.209 | -0,41 | 134,00 | -1.340.000 | 323.906.006 |
| 2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 210.743 | 1.188.920 | 21,54 | ||||
| 2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 722.590 | 1.865.767 | 63,21 | ||||
| 2022-09-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.427.209 | -0,41 | 129,68 | -1.296.800 | 314.760.463 |
| 2022-09-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.437.209 | -0,41 | 136,95 | -1.369.500 | 333.775.773 |
| 2022-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.447.209 | -0,41 | 165,24 | -1.652.400 | 404.376.815 |
| 2022-08-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.457.209 | -0,41 | 174,09 | -1.740.900 | 427.775.515 |
| 2022-08-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.467.209 | -0,40 | 167,99 | -1.679.900 | 414.466.440 |
| 2022-07-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.477.209 | -0,40 | 161,00 | -1.610.000 | 398.830.649 |
| 2022-07-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.487.209 | -0,40 | 167,00 | -1.670.000 | 415.363.903 |
| 2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.497.209 | -0,40 | 168,88 | -1.688.800 | 421.728.656 |
| 2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.497.209 | -0,40 | 168,88 | -1.688.800 | 421.728.656 |
| 2022-07-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.507.209 | -0,40 | 154,85 | -1.548.500 | 388.241.314 |
| 2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 5.825.495 | 5.825.495 | 3,15 | 18.350.309 | 18.350.309 | ||
| 2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 2.912.748 | 5.875.711 | 98,31 | 3,15 | 9.175.156 | 18.508.490 | |
| 2022-07-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.517.209 | -0,40 | 140,47 | -1.404.700 | 353.592.348 |
| 2022-06-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.527.209 | -0,39 | 127,69 | -1.276.900 | 322.699.317 |
| 2022-06-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.537.209 | -0,39 | 147,47 | -1.474.700 | 374.162.211 |
| 2022-06-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.547.209 | -0,39 | 146,31 | -1.463.100 | 372.682.149 |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 13.698.630 | 13.698.630 | 1,46 | 20.000.000 | 20.000.000 | ||
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 6.849.315 | 8.219.791 | 499,78 | 1,46 | 10.000.000 | 12.000.895 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.369.863 | 5.495.324 | 33,21 | 1,46 | 2.000.000 | 8.023.173 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.095.890 | 1.887.419 | 138,45 | 1,46 | 1.599.999 | 2.755.632 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 4.383.561 | 7.590.873 | 136,67 | 1,46 | 6.399.999 | 11.082.675 | |
| 2022-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.557.209 | -0,39 | 130,80 | -1.308.000 | 334.482.937 |
| 2022-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.567.209 | -0,39 | 138,38 | -1.383.800 | 355.250.381 |
| 2022-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -100 | 5.816.657 | 0,00 | 136,00 | -13.600 | 791.065.352 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -49.900 | 5.816.757 | -0,85 | 135,36 | -6.754.714 | 787.385.311 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -24.567 | 5.866.657 | -0,42 | 134,04 | -3.293.015 | 786.379.611 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -25.433 | 5.891.224 | -0,43 | 133,11 | -3.385.282 | 784.156.673 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31.618 | 5.916.657 | -0,53 | 132,22 | -4.180.674 | 782.327.013 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -51.256 | 5.948.275 | -0,85 | 131,45 | -6.737.478 | 781.886.473 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -41.182 | 5.999.531 | -0,68 | 130,08 | -5.356.765 | 780.391.395 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -75.944 | 6.040.713 | -1,24 | 129,39 | -9.826.257 | 781.596.982 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10.000 | 2.229.673 | -0,45 | 130,74 | -1.307.400 | 291.507.448 |
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
M - Exercise | -703 | 0 | -100,00 | ||||
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 5.415 | 5.415 | |||||
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 703 | 2.239.673 | 0,03 | ||||
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.579.843 | 4.465.866 | 54,74 | 1,91 | 3.017.500 | 8.529.804 | |
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 947.905 | 2.004.657 | 89,70 | 1,91 | 1.810.499 | 3.828.895 | |
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3.791.623 | 8.600.403 | 78,85 | 1,91 | 7.242.000 | 16.426.770 | |
| 2022-02-14 |
|
5 | MRNA |
Moderna, Inc.
Common Stock |
G - Gift | -100.000 | 2.238.970 | -4,28 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.666.666 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -5.000.000 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.666.667 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3.333.333 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -13.333.333 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -666.667 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.666.667 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.000.000 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -27.388.000 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -22.275.232 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4.112.000 | 0 | -100,00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 294.117 | 1.617.646 | 22,22 | 17,00 | 4.999.989 | 27.499.982 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1.323.529 | 1.323.529 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 661.764 | 5.514.707 | 13,64 | 17,00 | 11.249.988 | 93.750.019 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 4.852.943 | 4.852.943 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 970.588 | 970.588 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 220.588 | 8.617.413 | 2,63 | 17,00 | 3.749.996 | 146.496.021 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 8.396.825 | 8.396.825 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 5.896.386 | 5.896.386 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1.088.470 | 1.088.470 | |||||
| 2021-07-30 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 19.852 | 19.852 | |||||
| 2021-07-29 | 3 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
2.197.059 | ||||||||
| 2021-05-19 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -295.171 | 2.962.963 | -9,06 | ||||
| 2021-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
A - Award | 703 | 703 | |||||
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 4.081 | 4.081 | |||||
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4.888 | 9.116.657 | -0,05 | 121,07 | -591.810 | 1.103.790.130 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1.000 | 9.121.545 | -0,01 | 123,44 | -123.440 | 1.125.963.515 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -31.943 | 9.122.545 | -0,35 | 123,08 | -3.931.538 | 1.122.801.014 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -14.379 | 9.154.488 | -0,16 | 121,71 | -1.750.038 | 1.114.173.510 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -225.732 | 9.168.867 | -2,40 | 120,76 | -27.259.283 | 1.107.227.794 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -344.542 | 9.394.599 | -3,54 | 119,81 | -41.278.061 | 1.125.525.570 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -611.922 | 9.739.141 | -5,91 | 118,90 | -72.758.505 | 1.157.999.448 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -883.277 | 10.351.063 | -7,86 | 118,04 | -104.265.815 | 1.221.883.986 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -558 | 11.234.340 | 0,00 | 131,30 | -73.265 | 1.475.068.842 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6.610 | 11.234.898 | -0,06 | 130,56 | -862.994 | 1.466.814.801 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -83.242 | 11.241.508 | -0,74 | 129,54 | -10.783.377 | 1.456.253.050 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -123.374 | 11.324.750 | -1,08 | 128,74 | -15.883.527 | 1.457.981.157 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46.872 | 11.448.124 | -0,41 | 127,47 | -5.974.788 | 1.459.295.801 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -82.557 | 11.494.996 | -0,71 | 126,40 | -10.434.924 | 1.452.928.411 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -116.383 | 11.577.553 | -1,00 | 125,36 | -14.589.226 | 1.451.307.630 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -251.545 | 11.693.936 | -2,11 | 124,42 | -31.296.927 | 1.454.945.484 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -639.681 | 11.945.481 | -5,08 | 123,50 | -78.998.365 | 1.475.225.094 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -284.300 | 12.585.162 | -2,21 | 122,53 | -34.836.672 | 1.542.121.567 |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 2.633.703 | 2,73 | 29,00 | 2.030.000 | 76.377.387 | |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 2.633.703 | 2,73 | 29,00 | 2.030.000 | 76.377.387 | |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 15.393.593 | 0,46 | 29,00 | 2.030.000 | 446.414.197 | |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -23.423 | 14.623.159 | -0,16 | 151,29 | -3.543.551 | 2.212.266.072 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -190.710 | 14.646.582 | -1,29 | 150,51 | -28.704.468 | 2.204.511.249 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -179.268 | 14.837.292 | -1,19 | 149,63 | -26.823.154 | 2.220.044.653 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -268.688 | 15.016.560 | -1,76 | 148,52 | -39.905.810 | 2.230.274.508 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -292.483 | 15.285.248 | -1,88 | 147,57 | -43.162.565 | 2.255.688.375 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -307.795 | 15.577.731 | -1,94 | 146,64 | -45.134.105 | 2.284.270.183 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -357.316 | 15.885.526 | -2,20 | 145,48 | -51.982.439 | 2.311.031.088 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -405.551 | 16.242.842 | -2,44 | 144,55 | -58.623.573 | 2.347.949.915 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -397.126 | 16.648.393 | -2,33 | 143,57 | -57.017.127 | 2.390.283.036 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -117.011 | 17.045.519 | -0,68 | 142,76 | -16.704.549 | 2.433.426.815 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -70.631 | 17.162.530 | -0,41 | 141,46 | -9.991.271 | 2.427.765.155 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -102.852 | 17.233.161 | -0,59 | 140,24 | -14.423.553 | 2.416.709.566 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -56.435 | 17.336.013 | -0,32 | 139,64 | -7.880.849 | 2.420.882.335 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46.222 | 17.392.448 | -0,27 | 138,56 | -6.404.451 | 2.409.871.506 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122.142 | 17.438.670 | -0,70 | 137,29 | -16.768.948 | 2.394.165.468 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9.985 | 17.560.812 | -0,06 | 136,48 | -1.362.773 | 2.396.734.743 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30.968 | 17.570.797 | -0,18 | 170,03 | -5.265.421 | 2.987.523.958 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54.274 | 17.601.735 | -0,31 | 169,14 | -9.179.910 | 2.977.159.218 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -58.377 | 17.656.009 | -0,33 | 168,11 | -9.813.857 | 2.968.181.688 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122.715 | 17.714.386 | -0,69 | 167,10 | -20.505.750 | 2.960.084.529 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351.578 | 17.837.101 | -1,93 | 166,30 | -58.466.296 | 2.966.252.818 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -165.578 | 18.188.311 | -0,90 | 165,47 | -27.397.976 | 3.009.596.176 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -189.200 | 18.353.889 | -1,02 | 164,13 | -31.054.266 | 3.012.508.229 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -366.471 | 18.543.089 | -1,94 | 163,25 | -59.827.380 | 3.027.209.346 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250.501 | 18.909.560 | -1,31 | 162,36 | -40.672.044 | 3.070.209.108 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30.808 | 19.160.061 | -0,16 | 160,96 | -4.958.809 | 3.083.974.678 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54.409 | 19.190.869 | -0,28 | 160,37 | -8.725.620 | 3.077.656.933 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -161.887 | 19.245.278 | -0,83 | 159,18 | -25.769.076 | 3.063.451.805 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -35.000 | 12.869.462 | -0,27 | 150,41 | -5.264.350 | 1.935.695.779 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -99.005 | 12.904.462 | -0,76 | 148,91 | -14.742.765 | 1.921.594.403 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -267.038 | 13.003.467 | -2,01 | 148,01 | -39.523.921 | 1.924.624.946 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -288.656 | 13.270.505 | -2,13 | 147,17 | -42.481.157 | 1.953.004.296 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351.112 | 13.559.161 | -2,52 | 146,05 | -51.281.277 | 1.980.368.345 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -354.358 | 13.910.273 | -2,48 | 145,04 | -51.396.616 | 2.017.566.861 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -358.528 | 14.264.631 | -2,45 | 144,17 | -51.688.838 | 2.056.526.145 |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.667 | 738.333 | 10,75 | 11,50 | 824.170 | 8.490.830 | |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.667 | 738.333 | 10,75 | 11,50 | 824.170 | 8.490.830 | |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.666 | 1.685.444 | 4,44 | 11,50 | 824.159 | 19.382.606 | |
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11.585.199 | 0 | -100,00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11.441.326 | 0 | -100,00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -9.725.122 | 0 | -100,00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1.487.371 | 0 | -100,00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11.585.199 | 11.585.199 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11.441.326 | 11.441.326 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 9.725.122 | 9.725.122 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 1.487.371 | 1.487.371 | |||||
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 46.429 | 4.125.461 | 1,14 | 15,00 | 696.435 | 61.881.915 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37.143 | 1.370.476 | 2,79 | 15,00 | 557.145 | 20.557.140 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37.143 | 1.370.476 | 2,79 | 15,00 | 557.145 | 20.557.140 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 9.285 | 791.529 | 1,19 | 15,00 | 139.275 | 11.872.935 | |
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.481.481 | 0 | -100,00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -370.370 | 0 | -100,00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4.074.074 | 0 | -100,00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4.444.444 | 0 | -100,00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 1.481.481 | 1.481.481 | |||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 8.888.888 | 8.888.888 | |||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -43.154 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1.481.481 | 2.962.963 | -33,33 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1.186.310 | 3.258.134 | -26,69 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -966.234 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -642.180 | 1.283.282 | -33,35 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -3.587.820 | 4.434.600 | -44,72 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3.333.333 | 0 | -100,00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.666.666 | 0 | -100,00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.336.293 | 0 | -100,00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -8.333.333 | 0 | -100,00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -7.500.000 | 0 | -100,00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50.000 | 1.851.801 | 2,78 | 16,00 | 800.000 | 29.628.816 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50.000 | 1.851.801 | 2,78 | 16,00 | 800.000 | 29.628.816 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1.801.801 | 1.801.801 | |||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50.000 | 1.491.441 | 3,47 | 16,00 | 800.000 | 23.863.056 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1.441.441 | 1.441.441 | |||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 722.320 | 9.280.878 | 8,44 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4.504.504 | 8.558.558 | 111,11 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4.054.054 | 4.054.054 | |||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660.048 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660.048 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2.416.666 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2.416.666 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4.250.000 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4.250.000 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 165.000 | 1.143.177 | 16,87 | 15,00 | 2.475.000 | 17.147.655 | |
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95.861 | 978.177 | 10,86 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95.861 | 978.177 | 10,86 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338.630 | 882.316 | 62,28 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338.630 | 882.316 | 62,28 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543.686 | 543.686 | |||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543.686 | 543.686 | |||||
| 2020-10-13 | 3 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
485.949 | ||||||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2.053.049 | 0 | -100,00 | ||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.449.190 | 4.971.576 | -22,57 | ||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -7.550.810 | 14.435.589 | -34,34 | ||||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.666.667 | 4.079.032 | 69,09 | 3,75 | 6.250.001 | 15.296.370 | |
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.333.333 | 1.333.333 | 3,75 | 4.999.999 | 4.999.999 | ||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.333.333 | 1.333.333 | 3,75 | 4.999.999 | 4.999.999 | ||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 333.333 | 782.244 | 74,25 | 3,75 | 1.249.999 | 2.933.415 | |
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.666 | 666.666 | 7,50 | 4.999.995 | 4.999.995 | ||
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.667 | 2.910.972 | 29,70 | 7,50 | 5.000.002 | 21.832.290 | |
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.667 | 2.910.972 | 29,70 | 7,50 | 5.000.002 | 21.832.290 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -10.746 | 6.420.766 | -0,17 | 70,18 | -754.113 | 450.584.959 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -69.254 | 6.431.512 | -1,07 | 69,45 | -4.809.448 | 446.645.998 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -56.406 | 21.986.399 | -0,26 | 70,18 | -3.958.353 | 1.542.919.735 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -363.594 | 22.042.805 | -1,62 | 69,45 | -25.250.331 | 1.530.795.657 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -367 | 6.500.766 | -0,01 | 72,44 | -26.584 | 470.886.236 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -2.551 | 6.501.133 | -0,04 | 71,51 | -182.433 | 464.924.626 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -3.900 | 6.503.684 | -0,06 | 70,46 | -274.780 | 458.226.161 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -7.443 | 6.507.584 | -0,11 | 68,81 | -512.185 | 447.814.838 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23.199 | 6.515.027 | -0,35 | 67,15 | -1.557.822 | 437.486.669 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -42.540 | 6.538.226 | -0,65 | 65,77 | -2.797.690 | 429.993.625 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1.933 | 22.406.399 | -0,01 | 72,44 | -140.017 | 1.623.009.752 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -13.408 | 22.408.332 | -0,06 | 71,51 | -958.861 | 1.602.511.695 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -20.492 | 22.421.740 | -0,09 | 70,46 | -1.443.793 | 1.579.755.082 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -39.082 | 22.442.232 | -0,17 | 68,81 | -2.689.404 | 1.544.348.730 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -121.771 | 22.481.314 | -0,54 | 67,15 | -8.176.971 | 1.509.629.228 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -223.314 | 22.603.085 | -0,98 | 65,77 | -14.686.491 | 1.486.516.748 | |
| 2020-05-26 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.900.000 | 2.886.023 | 192,69 | 4,75 | 9.025.000 | 13.708.609 | |
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 380.000 | 1.056.752 | 56,15 | 4,75 | 1.805.000 | 5.019.572 | |
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.520.000 | 4.808.780 | 46,22 | 4,75 | 7.220.000 | 22.841.705 | |
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2.281.179 | 0 | -100,00 | ||||
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.610.000 | 6.580.766 | -19,66 | ||||
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -8.390.000 | 22.826.399 | -26,88 | ||||
| 2020-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 18.270 | 18.270 | |||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -38.366 | 8.190.766 | -0,47 | 18,65 | -715.710 | 152.797.102 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -199.935 | 31.216.399 | -0,64 | 18,65 | -3.729.747 | 582.335.680 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -4.092 | 8.229.132 | -0,05 | 18,96 | -77.579 | 156.012.822 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -21.325 | 31.416.334 | -0,07 | 18,96 | -404.292 | 595.609.710 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -27.714 | 8.233.224 | -0,34 | 18,99 | -526.408 | 156.384.327 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -144.423 | 31.437.659 | -0,46 | 18,99 | -2.743.199 | 597.133.183 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.735.720 | 0 | -100,00 | ||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.207.658 | 8.260.938 | -12,75 | ||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -6.292.342 | 31.582.082 | -16,61 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -248.379 | 0 | -100,00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -61.537 | 0 | -100,00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1.061.102 | 0 | -100,00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1.469.173 | 0 | -100,00 | ||||
| 2019-06-28 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 54.660 | 54.660 | |||||
| 2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4.444.444 | 4.444.444 | 2,25 | 9.999.999 | 9.999.999 | ||
| 2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4.444.444 | 4.444.444 | 2,25 | 9.999.999 | 9.999.999 | ||
| 2019-06-14 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2019-06-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 15.690 | 15.690 | |||||
| 2019-05-28 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -895.255 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -89.525 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -358.102 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -151.643 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -617.914 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -222.506 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -1.005.413 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -928.074 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -386.697 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -4.153.847 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -1.384.615 | 0 | -100,00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 500.000 | 986.023 | 102,88 | 20,00 | 10.000.000 | 19.720.460 | |
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 486.023 | 486.023 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 48.602 | 676.752 | 7,74 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 194.409 | 3.288.780 | 6,28 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 82.324 | 628.150 | 15,08 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 335.457 | 3.094.371 | 12,16 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 120.795 | 1.761.029 | 7,36 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 545.826 | 545.826 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 503.840 | 2.758.914 | 22,34 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 209.933 | 1.640.234 | 14,68 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 2.255.074 | 2.255.074 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 751.691 | 1.430.301 | 110,77 | ||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.682.665 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -450.958 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -600.000 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.257.465 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -992.110 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1.400.000 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.000.000 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 792.366 | 1.061.102 | 294,85 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 1.254.888 | 1.469.173 | 585,62 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 268.736 | 268.736 | |||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -940.579 | 0 | -100,00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 214.285 | 214.285 | |||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -750.000 | 0 | -100,00 | ||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1.251.251 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1.251.251 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -2.570.694 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -1.928.021 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -642.674 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1.278.720 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -852.480 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -9.275.111 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -3.091.704 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333.333 | 2.244.305 | 17,44 | 15,00 | 4.999.995 | 33.664.575 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333.333 | 2.244.305 | 17,44 | 15,00 | 4.999.995 | 33.664.575 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 266.667 | 2.560.096 | 11,63 | 15,00 | 4.000.005 | 38.401.440 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625.625 | 1.910.972 | 48,67 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625.625 | 1.910.972 | 48,67 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1.285.347 | 1.285.347 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 964.010 | 5.601.565 | 20,79 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 321.337 | 2.293.429 | 16,29 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 639.360 | 639.360 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 426.240 | 1.972.092 | 27,57 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 4.637.555 | 4.637.555 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1.545.852 | 1.545.852 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -562.407 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -347.173 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -1.331.816 | 0 | -100,00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 281.203 | 947.111 | 42,23 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 173.586 | 216.451 | 404,96 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 665.908 | 665.908 | |||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5.000.000 | ||||||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -21.496 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -85.989 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -1.428.432 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -5.713.739 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -6.195.632 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -24.782.551 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -1.823.036 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -7.292.145 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 21.496 | 9.468.596 | 0,23 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 85.989 | 37.874.424 | 0,23 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1.428.432 | 9.447.100 | 17,81 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 5.713.739 | 37.788.435 | 17,81 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 6.195.632 | 8.018.668 | 339,85 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 24.782.551 | 32.074.696 | 339,85 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1.823.036 | 1.823.036 | |||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 7.292.145 | 7.292.145 | |||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -781.860 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195.466 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195.466 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.781.843 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593.948 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593.948 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5.000.000 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5.000.000 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.830.402 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -15.323.593 | 0 | -100,00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 781.860 | 2.563.703 | 43,88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195.466 | 5.789.414 | 3,49 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195.466 | 5.789.414 | 3,49 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 1.781.843 | 1.781.843 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593.948 | 5.593.948 | 11,88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593.948 | 5.593.948 | 11,88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5.000.000 | 5.000.000 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5.000.000 | 5.000.000 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 3.830.402 | 3.830.402 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 15.323.593 | 15.323.593 | |||||
| 2018-07-18 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
| 2018-06-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -4.643.963 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -18.611.110 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-3 Preferred Stock |
C - Conversion | -8.333.000 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-2 Preferred Stock |
C - Conversion | -5.416.667 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -10.102.055 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -12.536.945 | 0 | -100,00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 281.250 | 18.233.403 | 1,57 | 16,00 | 4.500.000 | 291.734.448 | |
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
C - Conversion | 14.622.143 | 17.952.153 | 439,10 | ||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
| 2018-02-13 |
|
5 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
G - Gift | -24.527 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series C Preferred Stock |
C - Conversion | -352.800 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series B Preferred Stock |
C - Conversion | -1.533.214 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-2 Preferred Stock |
C - Conversion | -3.360.000 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-1 Preferred Stock |
C - Conversion | -1.280.000 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 109.770 | 2.030.495 | 5,72 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 477.042 | 1.920.725 | 33,04 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 1.045.426 | 1.443.683 | 262,50 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 398.257 | 398.257 | |||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Preferred Stock |
C - Conversion | -156.250 | 0 | -100,00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Preferred Stock |
C - Conversion | -125.000 | 0 | -100,00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Preferred Stock |
C - Conversion | -8.324.999 | 0 | -100,00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 8.606.249 | 8.918.749 | 2.754,00 | ||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625.000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625.000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625.000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625.000 | ||||||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -54.293 | 0 | -100,00 | ||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -306.222 | 612.442 | -33,33 | ||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -1.295.997 | 2.378.663 | -35,27 | ||||
| 2017-06-21 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10.293 | 106.787 | -8,79 | 3,10 | -31.908 | 331.040 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -41.178 | 426.885 | -8,80 | 3,10 | -127.652 | 1.323.344 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3.118 | 117.080 | -2,59 | 3,16 | -9.853 | 369.973 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12.482 | 468.063 | -2,60 | 3,16 | -39.443 | 1.479.079 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -47.090 | 120.198 | -28,15 | 3,17 | -149.275 | 381.028 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -188.367 | 480.545 | -28,16 | 3,17 | -597.123 | 1.523.328 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -28.163 | 167.288 | -14,41 | 3,18 | -89.558 | 531.976 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -112.731 | 668.912 | -14,42 | 3,18 | -358.485 | 2.127.140 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -64.509 | 195.451 | -24,81 | 3,75 | -241.909 | 732.941 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -258.214 | 781.643 | -24,83 | 3,75 | -968.302 | 2.931.161 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10.778 | 259.960 | -3,98 | 3,39 | -36.537 | 881.264 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -43.139 | 1.039.857 | -3,98 | 3,39 | -146.241 | 3.525.115 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -1.939 | 270.738 | -0,71 | 3,31 | -6.418 | 896.143 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -7.761 | 1.082.996 | -0,71 | 3,31 | -25.689 | 3.584.717 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -536 | 272.677 | -0,20 | 4,16 | -2.230 | 1.134.336 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -2.145 | 1.090.757 | -0,20 | 4,16 | -8.923 | 4.537.549 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8.802 | 273.213 | -3,12 | 4,18 | -36.792 | 1.142.030 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -35.209 | 1.092.902 | -3,12 | 4,18 | -147.174 | 4.568.330 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8.145 | 282.015 | -2,81 | 4,51 | -36.734 | 1.271.888 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -32.597 | 1.128.111 | -2,81 | 4,51 | -147.012 | 5.087.781 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -52.985 | 1.833.802 | -2,81 | 4,51 | -238.962 | 8.270.447 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3.108 | 290.160 | -1,06 | 4,63 | -14.390 | 1.343.441 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12.441 | 1.160.708 | -1,06 | 4,63 | -57.602 | 5.374.078 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -20.221 | 1.886.787 | -1,06 | 4,63 | -93.623 | 8.735.824 | |
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -50.271 | 0 | -100,00 | ||||
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -300.000 | 691.060 | -30,27 | ||||
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -1.200.000 | 2.764.256 | -30,27 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -444.995 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.779.981 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -1.500.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.000.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -200.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -800.000 | 0 | -100,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 80.000 | 918.664 | 9,54 | 12,50 | 1.000.000 | 11.483.300 | |
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 320.000 | 3.674.660 | 9,54 | 12,50 | 4.000.000 | 45.933.250 | |
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 118.665 | 838.664 | 16,48 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 474.661 | 3.354.660 | 16,48 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 400.000 | 719.999 | 125,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.600.000 | 2.879.999 | 125,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 266.666 | 319.999 | 500,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.066.666 | 1.279.999 | 500,00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 53.333 | 53.333 | |||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 213.333 | 213.333 | |||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -125.008 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -241.718 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -235.042 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -631.458 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -318.752 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 193.777 | 1.651.862 | 13,29 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 241.718 | 1.458.085 | 19,87 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 235.042 | 1.216.367 | 23,95 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 631.458 | 981.325 | 180,49 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 318.752 | 349.867 | 1.024,43 | ||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62.230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62.230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62.230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62.230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62.230 | ||||||||
| 2016-06-17 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -33.514 | 0 | -100,00 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 7 | 33.514 | 0,02 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 33.507 | 33.514 | 478.671,43 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -200.000 | 1.925.462 | -9,41 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -800.000 | 8.022.420 | -9,07 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -599.297 | 0 | -100,00 | 27,60 | -16.540.597 | ||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -80.141 | 1.925.462 | -4,00 | 27,60 | -2.211.892 | 53.142.751 | |
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -320.562 | 2.734.994 | -10,49 | 27,60 | -8.847.511 | 75.485.834 | |
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -199.999 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.051.060 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1.325.708 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -800.001 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4.204.240 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -5.302.834 | 0 | -100,00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 76.922 | 991.060 | 8,41 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 404.253 | 914.138 | 79,28 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 509.885 | 509.885 | |||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 307.692 | 3.964.256 | 8,41 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 1.617.015 | 3.656.564 | 79,28 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 2.039.549 | 2.039.549 | |||||
| 2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -2.508 | 0 | -100,00 | 0,56 | -1.404 | ||
| 2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -43.930 | 0 | -100,00 | 0,56 | -24.601 | ||
| 2015-11-20 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -508 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -3.256 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 58.232 | -0,05 | 2,27 | -73 | 132.187 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 508 | 58.264 | 0,88 | 0,14 | 71 | 8.157 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57.756 | -0,03 | 2,27 | -36 | 131.106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57.756 | -0,03 | 2,27 | -36 | 131.106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57.756 | -0,03 | 2,27 | -36 | 131.106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57.756 | -0,03 | 2,27 | -36 | 131.106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57.772 | 0,44 | 0,14 | 36 | 8.088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57.772 | 0,44 | 0,14 | 36 | 8.088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57.772 | 0,44 | 0,14 | 36 | 8.088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57.772 | 0,44 | 0,14 | 36 | 8.088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -206 | 56.804 | -0,36 | 2,27 | -468 | 128.945 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 3.256 | 57.010 | 6,06 | 0,14 | 456 | 7.981 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -8.410 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4.205 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4.205 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4.205 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4.205 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -53.857 | 0 | -100,00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -530 | 786.970 | -0,07 | 2,27 | -1.203 | 1.786.422 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 8.410 | 787.500 | 1,08 | 0,14 | 1.177 | 110.250 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779.090 | -0,03 | 2,27 | -602 | 1.768.534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779.090 | -0,03 | 2,27 | -602 | 1.768.534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779.090 | -0,03 | 2,27 | -602 | 1.768.534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779.090 | -0,03 | 2,27 | -602 | 1.768.534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4.205 | 779.355 | 0,54 | 0,14 | 589 | 109.110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4.205 | 779.355 | 0,54 | 0,14 | 589 | 109.110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4.205 | 779.355 | 0,54 | 0,14 | 589 | 109.110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4.205 | 779.355 | 0,54 | 0,14 | 589 | 109.110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -3.390 | 763.330 | -0,44 | 2,27 | -7.695 | 1.732.759 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 53.857 | 766.720 | 7,56 | 0,14 | 7.540 | 107.341 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 397.072 | 497.729 | 394,48 | 1,70 | 675.142 | 846.289 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 100.657 | 100.657 | |||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 53.465 | 67.018 | 394,49 | 1,70 | 90.907 | 113.951 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 13.553 | 13.553 | |||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 725.725 | 909.696 | 394,48 | 1,70 | 1.233.950 | 1.546.756 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 183.971 | 183.971 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -454.546 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.818.181 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -224.719 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -898.877 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -599.297 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.526.338 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6.105.362 | 0 | -100,00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 599.297 | 599.297 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 2.205.603 | 2.205.603 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 8.822.420 | 8.822.420 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 10.029 | 10.029 | |||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 164.528 | 175.718 | 1.470,31 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -2.484.192 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17.080 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17.080 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17.080 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2.484.192 | -0,02 | 0,46 | -283 | 1.142.728 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2.484.192 | -0,02 | 0,46 | -283 | 1.142.728 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17.080 | 2.484.808 | 0,69 | 0,02 | 342 | 49.696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17.080 | 2.484.808 | 0,69 | 0,02 | 342 | 49.696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17.080 | 2.484.808 | 0,69 | 0,02 | 342 | 49.696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 7.298.474 | -0,01 | 0,46 | -283 | 3.357.298 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98.570 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.729 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.729 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.729 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -850 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -499 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.570 | -0,06 | 0,46 | -29 | 45.342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.570 | -0,06 | 0,46 | -29 | 45.342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.570 | -0,06 | 0,46 | -29 | 45.342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.729 | 98.633 | 1,78 | 0,02 | 35 | 1.973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.729 | 98.633 | 1,78 | 0,02 | 35 | 1.973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.729 | 98.633 | 1,78 | 0,02 | 35 | 1.973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 93.572 | -0,03 | 0,46 | -15 | 43.043 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 850 | 93.604 | 0,92 | 0,02 | 17 | 1.872 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -39 | 92.754 | -0,04 | 0,46 | -18 | 42.667 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 499 | 92.793 | 0,54 | 0,04 | 20 | 3.712 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98.352 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.724 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.724 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.724 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -847 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -464 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.352 | -0,06 | 0,46 | -29 | 45.242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.352 | -0,06 | 0,46 | -29 | 45.242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98.352 | -0,06 | 0,46 | -29 | 45.242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.724 | 98.415 | 1,78 | 0,02 | 34 | 1.968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.724 | 98.415 | 1,78 | 0,02 | 34 | 1.968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1.724 | 98.415 | 1,78 | 0,02 | 34 | 1.968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -31 | 93.369 | -0,03 | 0,46 | -14 | 42.950 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 847 | 93.400 | 0,92 | 0,02 | 17 | 1.868 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -37 | 92.553 | -0,04 | 0,46 | -17 | 42.574 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 464 | 92.590 | 0,50 | 0,04 | 19 | 3.704 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 11.190 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -703.655 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12.183 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12.183 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12.183 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -5.988 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12.021 | 0 | -100,00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703.655 | -0,06 | 0,46 | -202 | 323.681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703.655 | -0,06 | 0,46 | -202 | 323.681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703.655 | -0,06 | 0,46 | -202 | 323.681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12.183 | 704.095 | 1,76 | 0,02 | 244 | 14.082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12.183 | 704.095 | 1,76 | 0,02 | 244 | 14.082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12.183 | 704.095 | 1,76 | 0,02 | 244 | 14.082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -216 | 668.426 | -0,03 | 0,46 | -99 | 307.476 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 5.988 | 668.642 | 0,90 | 0,02 | 120 | 13.373 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -927 | 662.654 | -0,14 | 0,46 | -426 | 304.821 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12.021 | 663.581 | 1,84 | 0,04 | 481 | 26.543 | |
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -631.133 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -629.851 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -819.493 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.053.201 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -774.527 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -128.567 | 0 | -100,00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 741.755 | 2.374.571 | 45,43 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 1.632.816 | 1.632.816 | |||||
| 2014-06-25 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
J - Other | -1.930.369 | 1.930.369 | -50,00 | ||||
| 2014-06-05 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4.205 | 4.205 | |||||
| 2014-03-24 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Stock Option |
A - Award | 16.143 | 16.143 | |||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | -525.500 | 0 | -100,00 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | -3.000.000 | 0 | -100,00 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 93.008 | 656.490 | 16,51 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 530.974 | 563.482 | 1.633,36 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -420.053 | 0 | -100,00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.680.213 | 0 | -100,00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.050.000 | 0 | -100,00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4.200.000 | 0 | -100,00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -9.000.000 | 0 | -100,00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 32.912 | 293.268 | 12,64 | 10,00 | 329.120 | 2.932.680 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 131.722 | 1.173.149 | 12,65 | 10,00 | 1.317.220 | 11.731.490 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 214.095 | 1.907.008 | 12,65 | 10,00 | 2.140.950 | 19.070.080 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 231.504 | 260.356 | 802,38 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 926.017 | 1.041.427 | 802,37 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1.417.323 | 1.692.913 | 514,29 | ||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65.016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65.016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65.016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65.016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65.016 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
275.590 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
115.410 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
28.852 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
No securities are beneficially owned |
0 | ||||||||
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -20.300 | 1.693.551 | -1,18 | 24,09 | -489.027 | 40.797.644 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -904 | 1.713.851 | -0,05 | 25,10 | -22.690 | 43.017.660 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -54.000 | 1.714.755 | -3,05 | 24,20 | -1.306.800 | 41.497.071 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -155.583 | 1.768.755 | -8,09 | 25,03 | -3.894.242 | 44.271.938 | |
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series D Preferred Stock |
C - Conversion | -407.060 | 0 | -100,00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C-1 Preferred Stock |
C - Conversion | -333.288 | 0 | -100,00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C Preferred Stock |
C - Conversion | -416.667 | 0 | -100,00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series B Preferred Stock |
C - Conversion | -1.900.000 | 0 | -100,00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series A Preferred Stock |
C - Conversion | -984.640 | 0 | -100,00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
P - Purchase | 20.000 | 1.562.616 | 1,30 | 15,00 | 300.000 | 23.439.240 | |
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
C - Conversion | 1.542.616 | 1.542.616 | |||||
| 2013-09-18 | 3 | XLRN |
ACCELERON PHARMA INC
Common Stock |
4.867 | ||||||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series C-2 Convertible Preferred Stock |
C - Conversion | -617.031 | 0 | -100,00 | ||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -10.000.000 | 0 | -100,00 | ||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 3.860.738 | 3.860.738 | |||||
| 2013-06-14 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4.205 | 4.205 | |||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series B Preferred Stock |
C - Conversion | -4.131.552 | 0 | -100,00 | ||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series A Preferred Stock |
C - Conversion | -8.640.289 | 0 | -100,00 | ||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
P - Purchase | 107.142 | 1.924.339 | 5,90 | 14,00 | 1.499.988 | 26.940.746 | |
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 550.873 | 1.817.197 | 43,50 | 7,73 | 4.258.248 | 14.046.933 | |
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 1.152.039 | 1.266.324 | 1.008,04 | 5,25 | 6.048.205 | 6.648.201 | |
| 2013-05-08 | 3 | RCPT |
Receptos, Inc.
Common Stock |
114.285 | ||||||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -19.544.924 | 0 | -100,00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -9.626.604 | 0 | -100,00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series B Convertible Participating Preferred Stock |
C - Conversion | -11.422.045 | 0 | -100,00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-2 Convertible Participating Preferred Stock |
C - Conversion | -2.726.088 | 0 | -100,00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-1 Convertible Participating Preferred Stock |
C - Conversion | -2.090.000 | 0 | -100,00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 491.824 | 1.165.786 | 72,98 | 7,00 | 3.442.768 | 8.160.502 | |
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 673.962 | 673.962 | |||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 331.953 | 891.887 | 59,28 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 393.863 | 559.934 | 237,17 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 94.003 | 166.071 | 130,44 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 72.068 | 72.068 | |||||
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 1.050.000 | 1.764.286 | 147,00 | 2,00 | 2.100.000 | 3.528.572 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 500.000 | 2.851.447 | 21,26 | 2,00 | 1.000.000 | 5.702.894 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 75.000 | 215.013 | 53,57 | 2,00 | 150.000 | 430.026 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 125.000 | 651.560 | 23,74 | 2,00 | 250.000 | 1.303.120 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 250.000 | 2.434.800 | 11,44 | 2,00 | 500.000 | 4.869.600 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -298.137 | 0 | -100,00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6.422 | 0 | -100,00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6.422 | 0 | -100,00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6.422 | 0 | -100,00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2.353 | 0 | -100,00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298.137 | -0,01 | 5,83 | -134 | 1.738.139 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298.137 | -0,01 | 5,83 | -134 | 1.738.139 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6.422 | 298.160 | 2,20 | 0,02 | 128 | 5.963 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6.422 | 298.160 | 2,20 | 0,02 | 128 | 5.963 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 285.339 | -0,01 | 5,83 | -134 | 1.663.526 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6.422 | 285.362 | 2,30 | 0,02 | 128 | 5.707 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -13 | 278.940 | 0,00 | 5,83 | -76 | 1.626.220 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2.353 | 278.953 | 0,85 | 0,03 | 71 | 8.369 | |
| 2012-06-13 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4.205 | 4.205 | |||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -130.867 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7.001 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7.001 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7.001 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2.580 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2.497 | 0 | -100,00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130.867 | -0,03 | 3,95 | -142 | 516.925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130.867 | -0,03 | 3,95 | -142 | 516.925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130.867 | -0,03 | 3,95 | -142 | 516.925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7.001 | 130.903 | 5,65 | 0,02 | 140 | 2.618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7.001 | 130.903 | 5,65 | 0,02 | 140 | 2.618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7.001 | 130.903 | 5,65 | 0,02 | 140 | 2.618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -14 | 109.972 | -0,01 | 3,95 | -55 | 434.389 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2.580 | 109.986 | 2,40 | 0,02 | 52 | 2.200 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -19 | 107.406 | -0,02 | 3,95 | -75 | 424.254 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2.497 | 107.425 | 2,38 | 0,03 | 75 | 3.223 | |
| 2012-02-29 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4.205 | 4.205 |
